Roberta Sgariglia

List of Publications by Citations

Source: https://exaly.com/author-pdf/11436229/roberta-sgariglia-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32 papers	520 citations	12 h-index	22 g-index
32 ext. papers	705 ext. citations	3.9 avg, IF	3.55 L-index

#	Paper	IF	Citations
32	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. *British Journal of Cancer*, **2017**, 116, 802-810	8.7	93
31	Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. *Journal of Clinical Pathology*, **2015**, 68, 64-8	3.9	67
30	Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. *Journal of Clinical Pathology*, **2016**, 69, 767-71	3.9	56
29	Cell free DNA analysis by SiRe next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. *Journal of Thoracic Disease*, **2017**, 9, S1383-S1390	2.6	31
28	mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. *Journal of Thoracic Disease*, **2020**, 12, 3836-3843	2.6	29
27	Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. *Cancer Cytopathology*, **2020**, 128, 107-118	3.9	26
26	Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. *Cancer Cytopathology*, **2018**, 126, 317-325	3.9	25
25	Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. *Journal of Clinical Pathology*, **2019**, 72, 38-45	3.9	25
24	Tumor mutational burden on cytological samples: A pilot study. *Cancer Cytopathology*, **2021**, 129, 460-467	3.9	22
23	UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. *Molecular Carcinogenesis*, **2016**, 55, 793-807	5	18
22	Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?. *Cancer Cytopathology*, **2016**, 124, 776-784	3.9	16
21	Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. *Journal of Clinical Pathology*, **2017**, 70, 803-806	3.9	13
20	KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. *Journal of Clinical Pathology*, **2015**, 68, 265-9	3.9	11
19	Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis. *Diagnostic Cytopathology*, **2020**, 48, 300-307	1.4	11
18	BRAF: A Two-Faced Janus. *Cells*, **2020**, 9,	7.9	10
17	Predictive molecular pathology in the time of COVID-19. *Journal of Clinical Pathology*, **2021**, 74, 234-237	3.9	8
16	Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic. *Endocrine*, **2021**, 71, 20-25	4	8

List of Publications

15	Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer. *Frontiers in Medicine*, **2021**, 8, 633923	4.9	7
14	Next generation sequencing in cytology. *Cytopathology*, **2021**, 32, 588-595	1.3	6
13	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. *Cancers*, **2021**, 13,	6.6	6
12	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe Panel. *Frontiers in Oncology*, **2020**, 10, 236	5.3	5
11	EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. *Journal of Clinical Pathology*, **2015**, 68, 739-41	3.9	5
10	Liquid biopsy for mutations testing in non-small cell lung cancer: a retrospective study. *Journal of Clinical Pathology*, **2020**,	3.9	5
9	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. *Journal of Clinical Pathology*, **2021**,	3.9	4
8	Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. *Cells*, **2021**, 10,	7.9	4
7	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. *Journal of Molecular Pathology*, **2021**, 2, 241-254	0.4	3
6	Liquid Biopsy Is a Promising Tool for Genetic Testing in Idiopathic Pulmonary Fibrosis. *Diagnostics*, **2021**, 11,	3.8	2
5	A 45-Year Old Man With An Intraventricular Mass. *Brain Pathology*, **2020**, 30, 405-406	6	1
4	Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel. *Journal of Clinical Pathology*, **2021**,	3.9	1
3	Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer. *Journal of Clinical Pathology*, **2021**,	3.9	1
2	Molecular Testing of Thyroid Fine-Needle Aspiration: Local Issues and Solutions. An Interventional Cytopathologist Perspective. *Journal of Molecular Pathology*, **2021**, 2, 233-240	0.4	1
1	Methods for actionable gene fusion detection in lung cancer: now and in the future. *Pharmacogenomics*, **2021**, 22, 833-847	2.6	0